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Ikegami, Machiko, Timothy D. Le Cras, William D. Hardie,
Mildred T. Stahlman, Jeffrey A. Whitsett, and Thomas R. Korf-
hagen. TGF- perturbs surfactant homeostasis in vivo. Am J Physiol
Lung Cell Mol Physiol 289: L34–L43, 2005. First published March
11, 2005; doi:10.1152/ajplung.00407.2004.—To determine potential
relationships between transforming growth factor (TGF)- and sur-
factant homeostasis, the metabolism, function, and composition of
surfactant phospholipid and proteins were assessed in transgenic mice
in which TGF- was expressed in respiratory epithelial cells. Secre-
tion of saturated phosphatidylcholine was decreased 40–60% by
expression of TGF-. Although SP-A, SP-B, and SP-C mRNA levels
were unchanged by expression of TGF-, SP-A and SP-B content in
bronchoalveolar lavage ﬂuid was decreased. The minimum surface
tension of surfactant isolated from the transgenic mice was signiﬁ-
cantly increased. Incubation of cultured normal mice type II cells with
TGF- in vitro did not change secretion of surfactant phosphatidyl-
choline and SP-B, indicating that TGF- does not directly inﬂuence
surfactant secretion. Expression of a dominant negative (mutant) EGF
receptor in the respiratory epithelium blocked the TGF--induced
changes in lung morphology and surfactant secretion, indicating that
EGF receptor signaling in distal epithelial cells was required for
TGF- effects on surfactant homeostasis. Because many epithelial
cells were embedded in ﬁbrotic lesions caused by TGF-, changes in
surfactant homeostasis may at least in part be inﬂuenced by tissue
remodeling that results in decreased surfactant secretion. The number
of nonembedded type II cells was decreased 30% when TGF- was
expressed during development and was increased threefold by TGF-
expression in adulthood, suggesting possible alteration of type II cells
on surfactant metabolism in the adult lung. Abnormalities in surfac-
tant function and decreased surfactant level in the airways may
contribute to the pathophysiology induced by TGF- in both the
developing and adult lung.
bronchopulmonary dysplasia; acute respiratory distress syndrome;
pulmonary ﬁbrosis; surface activity of surfactant
TRANSFORMING GROWTH FACTOR- (TGF-) is a member of the
epidermal growth factor (EGF) family of polypeptides that is
expressed in the developing and adult human lung airways and
alveolar epithelial cells (46, 48). Increased expression of
TGF- and EGF receptor (EGFR) ligands was associated with
a number of diseases characterized by lung remodeling. Levels
of TGF- in tracheal aspirates from infants with developing
bronchopulmonary dysplasia (BPD) were increased compared
with premature infants that did not develop BPD (46, 48).
Likewise, TGF- was increased in bronchoalveolar lavage
ﬂuid (BALF) of patients with acute respiratory distress syn-
drome (4, 31) and in alveolar macrophages, epithelial cells, and
ﬁbroblasts following lung injury (28–30, 51).
Remodeling of both vascular and alveolar compartments of
the lung is associated with abnormal lung mechanics, including
decreased compliance and increased airway resistance (8, 19,
36, 37). Increased surfactant synthesis and decreased surfactant
secretion have been reported in a premature baboon model of
BPD induced by ventilation (45). Saturated phosphatidylcho-
line (Sat PC) concentration in tracheal aspirates from infants
dying of BPD was 60% lower in infants of similar age
recovered from respiratory distress syndrome (7). Furthermore,
surfactant protein content and surfactant function were altered
in the samples from patients with BPD and lung injury (9, 14,
15, 23, 25, 37, 44, 52). Thus not only the morphological
changes but also decreased surfactant secretion may contribute
to altered pulmonary function in BPD. Whereas increased
expression of TGF- has been associated with BPD and other
forms of lung injury, the effect of increased TGF- on surfac-
tant homeostasis is unknown.
To determine whether TGF- inﬂuenced lung function, we
previously generated transgenic mice in which TGF- was
expressed in epithelial cells of the peripheral lung under the
control of the surfactant protein (SP)-C promoter (SP-C-
TGF- mice) (26). TGF- caused dose-dependent lung remod-
eling, including disruption of postnatal alveolarization and
pulmonary vascular morphogenesis (27), as well as pleural and
parenchymal ﬁbrosis (18). To determine the effects of TGF-
n lung remodeling in the adult, TGF- was conditionally
expressed in respiratory epithelial cells under control of the
Clara cell secretory protein promoter reverse tetracycline-
responsive transactivator, CCSPrtTA//(tetO)7TGF-/
mice (17). In these mice, TGF- is induced by treating the
mice with doxycycline (Dox). To understand the role of TGF-
in altered surfactant homeostasis in the remodeled lung, sur-
factant metabolism and function were studied in transgenic
mice in which TGF- was increased during development and
adulthood.
METHODS
Mice
Studies were approved by the Institutional Animal Care and Use
Committee of the Cincinnati Children’s Hospital Research Founda-
tion. Mice were maintained in a barrier containment facility. All mice
appeared healthy and were without evidence of infection. Sentinel
mice in the colony were serologically negative for common murine
pathogens.
SP-C-TGF- mice. Eight- to 10-wk-old FVB/N transgenic mice
expressing human TGF- under control of the human SP-C as
promoter were studied (26). The lung content of TGF- in line 28
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to 2.45  0.60 ng/lung of TGF- compared with 0.58  0.05 ng/lung
littermate nontransgenic mice (18). In this model, TGF- was ex-
pressed in respiratory epithelial cells throughout development.
Conditional expression of TGF-. Transgenic mice expressing the
rtTA protein under control of the rat CCSP gene promoter (CCSPrtTA)
(49) were bred with transgenic mice bearing (tetO)7TGF-/. These
bitransgenic mice have normal lung structure (17). In these bitrans-
genic mice, Dox induces the expression of TGF- in the lung (17). In
the present study, 6-wk-old mice were treated with Dox containing
drinking water for 6 wk and studied at 12 wk of age. At this time,
ﬁbrosis and emphysema were observed (17). The control group
consisted of 12-wk-old single transgenic CCSP-rtTA/ littermates
that were also treated in an identical manner with Dox.
SP-C-TGF-,SP-C-EGFR-M mice. The SP-C-EGFR-M transgenic
mice express a truncated EGFR lacking a portion of the cytoplasmic
domain in distal epithelial cells of the lung. This EGFR acts as a
dominant negative inhibition of EGFR signaling. SP-C-EGFR-M
transgenic mice were bred with SP-C-TGF- mice, creating SP-C-
TGF-,SP-C-EGFR-M mice (16). TGF--induced ﬁbrosis was re-
versed, and the extent of alveolar enlargement was signiﬁcantly
decreased compared with SP-C-TGF- mice (16). Surfactant phos-
pholipid metabolism was studied in 10-wk-old SP-C-TGF-
,EGFR-M mice to determine whether EGFR signaling in the respi-
ratory epithelium mediated surfactant abnormalities in these mice.
Sat PC Pool Size
Mice were anesthetized with intraperitoneal pentobarbital sodium
and exsanguinated by transection of the distal aorta. A 20-gauge blunt
needle was tied into the trachea, the chest wall was opened, and 0.9%
NaCl was ﬂushed into the airways until the lungs were fully expanded
(1 ml). The ﬂuid was then withdrawn by syringe, and saline lavage
was repeated ﬁve times. BALF was pooled and volume was measured.
The lavaged lung tissue was homogenized in 0.9% NaCl. Aliquots of
BALF and the lung homogenates were extracted with chloroform-
methanol (2:1, by volume), Sat PC was isolated by OsO4 oxidation
followed by column chromatography (32), and Sat PC was quantiﬁed
by measuring phosphorus (3). Sat PC pool size measurements were in
eight to ﬁfteen mice for each genotype group.
Surfactant Phospholipid Precursor Incorporation Into Sat PC
Mice were given intraperitoneal injections of 10 l/g body wt of
0.9% NaCl containing 0.5 Ci [3H]palmitic acid. Groups of seven to
nine mice were killed at 8 h (and 16 h for SP-C-TGF- mice) after
injection of radiolabeled precursor. BALF was recovered from each
animal, and lung tissue was homogenized in saline. Sat PC was
isolated from BALF and lung homogenate as described above, and
radioactivity was measured (20). The percent secretion of labeled Sat
PC was calculated as the percent of radioactivity in Sat PC in BALF
relative to the radioactivity in Sat PC in total lung (BALF  lung
tissue).
Morphological Analysis
Lungs were inﬂation ﬁxed at 25 cmH2O with 4% paraformalde-
hyde. The volume of the lung was determined by the displacement
Fig. 1. Increased saturated phosphatidylcholine (Sat PC) in lung tissue and
decreased secreted Sat PC in surfactant protein (SP)-C-transforming growth
factor (TGF)- mice. A: surfactant Sat PC levels were compared between
SP-C-TGF- mice and nontransgenic mice. Sat PC was increased in lung
tissue and total lung [bronchoalveolar lavage ﬂuid (BALF)  lung tissue] but
was decreased in BALF of SP-C-TGF- mice. B: secreted Sat PC in mouse
lungs was determined as percent Sat PC in BALF relative to Sat PC in total
lung. Secreted Sat PC was decreased in SP-C-TGF- mice. N  15 mice/
group; *P 	 0.05 vs. nontransgenic mice.
Fig. 2. Increased incorporation of [3H]palmitic acid into Sat PC with de-
creased secretion in SP-C-TGF- mice. Radioactivity (counts per minute,
cpm) of [3H]Sat PC in BALF, lung tissue, and total lung (BALF  lung tissue)
was determined as described in METHODS 8( A) and 16 (B) h after [3H]palmitic
acid intraperitoneal injection in SP-C-TGF- mice and littermate nontrans-
genic mice. The amount of radioactivity injected was adjusted to body weight
of each mouse. At both 8 and 16 h after labeled surfactant precursor injection,
[3H]palmitic acid incorporated into Sat PC was signiﬁcantly higher in SP-C-
TGF- transgenic lung tissue but decreased in BALF of SP-C-TGF- mice.
The percentage of [3H]Sat PC in BALF relative to [3H]Sat PC in total lung was
calculated for 8 (C) and 16 (D) h after radiolabeled precursor injection. N 
7–8 mice/group; *P 	 0.05 vs. nontransgenic mice.
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alcohol and divided into ﬁve regions: left lobe, right cardiac lobe,
right apical lobe, right diaphragmatic lobe, and accessory lobe. Each
of the lobes was bisected perpendicularly to the lateral axis and
embedded in parafﬁn. Ten parafﬁn sections were cut (5 m) for each
block and serially numbered. The following 20 sequential slices were
discarded. This process was repeated ﬁve times to obtain ﬁve non-
overlapping regions of the lung. A random number generated from the
Random Numbers Table was used to select the slide number (47) from
each of the ﬁve levels for SP-C proprotein staining (53). An area
measurement of each of the lung pieces was obtained using Meta-
morph Software (version 6.1; Universal Imaging, West Chester, PA)
calibrated to 5.33 m2 per pixel. A known area (92 mm2) generated
by three random coordinate pairs was sampled in each lung piece to
determine the number of alveolar type II cells (150 ﬁelds counted/
mouse). Alveolar type II cells were identiﬁed by SP-C proprotein
immunostaining from each ﬁeld as cells possessing a cytoplasmic
proﬁle restricted to 18–72 m2 (47). Additionally, a determination of
lung parenchyma and ﬁbrotic region in parenchyma was made on the
tissue stained with hematoxylin and eosin using a 121-line test lattice
grid superimposed onto each image to count the number of times the
intercepts of the lines interacted with alveolar tissue. The ﬁbrotic
region recognized by light microscope was counted, and all the
morphological analyses were done blindly by one experienced re-
search assistant. Three to four mice were studied in each group. The
numerical density (Nd) of type II cells at each level was determined by
counting the number of cells in the given area and multiplying by the
thickness (5 m) of the tissue slice. The total number of alveolar type
II cells in the lung was obtained by multiplying the averaged Nd for
ﬁve levels by the volume of the lung minus a shrinkage factor of 25%
due to parafﬁn processing (47) and multiplying by the average
parenchymal tissue in the lung. The percent of type II cells embedded
in ﬁbrotic lesions relative to the total number of type II cells was
determined in three ﬁelds from slices of ﬁve levels from the left lung
and right lower lobe. Electron microscopy was performed on lung
tissue from SP-C-TGF- mice and nontransgenic control mice after
inﬂation ﬁxation at 25 cmH2O in glutaraldehyde.
Surfactant Protein and mRNA Analysis
The contents of SP-A, -B, -C, and -D in BALF were analyzed by
Western blot. Samples containing 1.25 nmol of Sat PC were used for
SP-A and SP-D, 0.22 nmol of Sat PC were used for analysis of SP-B,
and 0.65 nmol of Sat PC were used for SP-C. Antisera for SP-B and
SP-D were from Chemicon (Temecula, CA). Guinea pig anti-rat SP-A
and rabbit anti-recombinant human SP-C were used for SP-A and
SP-C, and immunoreactive bands were quantitated by densitometric
analyses as described previously (22, 39). S1 nuclease protection
assays were performed as described previously (2) using lung tissues
Fig. 3. Induced expression of TGF- in adult lungs causes increased Sat PC in
lung tissue and decreased Sat PC secretion. A: Sat PC levels. B: incorporation
of [3H]palmitic acid into Sat PC 8 h after [3H]palmitic acid intraperitoneal
injection was determined in BALF, lung tissue, and total lung of BALF 
tissue on conditional CCSPrtTA//(tetO)7TGF-/ mice that were treated
with doxycycline to induce TGF- for 6 wk. The control mice were single
transgenic CCSPrtTA/ mice not treated with doxycycline. Sat PC level and
incorporation of radiolabeled precursor into Sat PC was increased in the lung
tissue (A and B). Calculated percent secretion of Sat PC (C) and [3H]Sat PC
(D) was signiﬁcantly decreased in CCSPrtTA//(tetO)7TGF-/ mice. N 
7 mice/group; *P 	 0.05 vs. control mice.
Fig. 4. Localization of type II cells in SP-C-TGF- mice. Type II cells were
identiﬁed by immunostaining with pro-SP-C antibody (arrows). A: nontrans-
genic mice; normal distribution of type II cells. B: SP-C-TGF- mice; type II
cells were detected within ﬁbrotic lesions of alveolar septae. These images are
representative of lung sections from 4 distinct mice. Scale bars are 50 m.
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ribosomal protein L32 as an internal control.
Surfactant Function
Large aggregate surfactant was isolated from pooled BALF by
centrifugation at 40,000 g for 15 min over 0.8 M sucrose in 0.9%
NaCl cushion. Surface activity was measured with a captive bubble
surfactometer (21, 42). The concentration of each sample was ad-
justed to 7 nmol of phospholipid/l, and 3 l of the sample was
applied to the air-water interface of a 25-l volume bubble by
microsyringe (n  3 pool, 2 mice/pool). Surface tension was mea-
sured every 10 s for 300 s to establish equilibrium surface tension, and
then bubble pulsation was started. The minimum surface tension after
80% bubble volume reduction was measured, which did not change
signiﬁcantly after the third pulsation. The minimum surface tension at
the ﬁfth pulsation was reported.
Effect of TGF- on Surfactant Secretion by Cultured Type II Cells
To determine whether TGF- directly affects type II cell surfactant
secretion, type II cells were isolated from normal FVB/N mice and
cultured as previously reported (39). Combined type II cells isolated
from four mice were seeded into 12 wells and cultured on Matrigel
matrix in bronchial epithelial cell growth media (BEGM) containing
5% charcoal-stripped fetal bovine serum and 10 ng/ml of keratinocyte
growth factor (39). The purity of type II cell preparations was 
90%
as assessed by modiﬁed PAP stain (10). It was previously shown that
under these conditions, synthesis and secretion of surfactant by
murine type II cells decline on day 1 of culture but recover by day 3,
reaching levels comparable to or exceeding freshly isolated cells by
day 5 (39). Effects of 5, 50, and 250 ng/well of TGF- on [3H]PC
secretion were assessed as previously described. The recombinant
human TGF- (R&D Systems, Minneapolis, MN) had low endotoxin
levels (	0.1 ng/1 g TGF-) and was used within 3 wk after
purchase. Murine cells were labeled with 1 Ci/ml of [3H]choline for
48 h before assay on 7 days in culture. Cells were washed three times
to remove free labels, and TGF- was added. Media were removed
3 h after incubation with TGF-, and the cells were rinsed. Media
samples were combined, and the cells were removed by centrifugation
(130 g for 8 min). Phospholipids from the total cell and media samples
were extracted with methanol and chloroform, and radioactivities
were determined. The percent PC secretion was calculated as radio-
activity in media divided by total radioactivity in media  cells  100.
To evaluate whether TGF- inﬂuences SP-B secretion, type II cells
were used on day 7 of culture. Cells were washed three times with
BEGM to remove extracellular surfactant, and TGF- (0, 5, 50, and
250 ng/well) was added. Media were removed after 3 h, and cells were
rinsed with fresh media. The media samples were combined, and
surfactant was isolated by centrifugation as in previous studies (39).
The level of SP-B in isolated surfactant from each well media was
determined by Western blotting. SP-B secretion was quantitated by
scanning densitometry and expressed relative to control wells lacking
TGF-.
Data Analysis
Results are presented as means  SE. Two group comparisons
were carried out using unpaired Student’s t-tests. The comparisons for
in vitro cultured type II cell study was by one-way ANOVA and
Tukey-Kramer multiple comparisons tests. Signiﬁcance was accepted
at P 	 0.05.
RESULTS
Surfactant Metabolism
Effects of constitutive expression of TGF- in developing
and adult lungs: SP-C-TGF- mice. In the SP-C-TGF- mice,
TGF- is constitutively expressed throughout lung develop-
ment to adulthood. In adult SP-C-TGF- mice, Sat PC levels in
Fig. 5. Localization of type II cells in ﬁ-
brotic lesion of SP-C-TGF- mice. A and C:
type II cells were detected in nontransgenic
mice by transmission electron microscope. B
and D: type II cells were embedded in ﬁ-
brotic lesions in SP-C-TGF- mice. Type II
cells are indicated by arrows and lamellar
bodies by arrowheads. Images are represen-
tative of lung sections from 4 distinct mice.
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littermate nontransgenic mice. In contrast, Sat PC content in
lung tissue was increased 1.5-fold in SP-C-TGF- mice (Fig.
1A). Secreted Sat PC (in BALF) relative to Sat PC in the total
lung (BALF  tissue) was decreased by 60% in SP-C-TGF-
mice (Fig. 1B), and radiolabeled Sat PC incorporation in BALF
was decreased 8 and 16 h after radiolabeled precursor injection
(P 	 0.05; Fig. 2, A and B). Expression of TGF- increased
radiolabeled Sat PC in lung tissue by approximately twofold
(Fig. 2, A and B) and decreased [3H]Sat PC secretion into the
alveolus by 60% 8 and 16 h after injection (Fig. 2, C and D).
Conditional expression of TGF- in adult lung. To avoid the
possible effects of TGF- during lung morphogenesis, we
assessed the effects of increased TGF- on surfactant metab-
olism in the adult lung in which TGF- was expressed in a
conditional manner. Surfactant Sat PC pool sizes, surfactant
protein composition, and surfactant secretion were determined
in CCSPrtTA//(tetO)7TGF-/ mice in which TGF- is
conditionally expressed only when the mouse is exposed to
Dox. Surfactant pool size and metabolism were determined in
CCSPrtTA//(tetO)7TGF-/ mice treated with Dox from
6–12 wk of age. Sat PC levels in BALF were decreased,
whereas total content of Sat PC in the lung was increased in
CCSPrtTA//(tetO)7TGF-/ mice (Fig. 3A). As seen in
SP-C-TGF- mice, induction of TGF- expression caused
decreased secretion of Sat PC (Sat PC in BALF relative to total
lung) by 40% (Fig. 3C). Eight hours after [3H]palmitic acid
injection, [3H]Sat PC incorporated from [3H]palmitic acid in
lung tissue was increased (Fig. 3B) and percent secretion of
[3H]Sat PC was markedly decreased in TGF--expressing
mice (Fig. 3D). Thus TGF- expression during lung devel-
opment (SP-C-TGF-) or in adult lungs [CCSPrtTA//
(tetO)7TGF-/] led to similar alterations in surfactant
content.
Effects of TGF- on Lung Morphology
SP-C-TGF- mice. As previously reported (17, 18, 26),
pleural and peribronchioalveolar perivascular ﬁbrosis and en-
larged alveoli were observed in SP-C-TGF- transgenic mice.
Numerous type II cells, identiﬁed by pro-SP-C immunostain-
ing, were embedded within ﬁbrotic lesions (Fig. 4B), an ob-
servation that was conﬁrmed by electron microscopy (Fig. 5).
Although type II cell ultrastructure was preserved, the cells that
were embedded within ﬁbrotic lesions thus had limiting access
to the alveoli.
CCSPrtTA//(tetO)7TGF-/ mice. Alveolar enlarge-
ment, as well as pleural and perivascular ﬁbrosis, also was
observed in CCSPrtTA//(tetO)7TGF-/ mice after treat-
ment with Dox from 6 to 12 wk of age. As in SP-C-TGF-
mice, type II cells were embedded in ﬁbrotic lesions (Fig. 6B).
Qualitatively, the ﬁbrotic area within which type II cells were
embedded was not as extensive as that characteristic of SP-C-
TGF- mice.
Morphological analysis. Expression of TGF- in SP-C-
TGF- mice resulted in lower body weight (Table 1). Whereas
total lung volumes were not signiﬁcantly changed, lung vol-
ume relative to body weight was signiﬁcantly greater in TGF-
-expressing mice. Parenchymal volume was signiﬁcantly de-
creased in SP-C-TGF- mice, reﬂecting enlarged air spaces.
Whereas percent parenchyma was unchanged in adult mice
with conditionally expressed TGF-, lung volume was in-
creased 1.5-fold, reﬂecting an increase in air space. Enlarged
air spaces were observed in both SP-C-TGF- mice and
CCSPrtTA//(tetO)7TGF-/ on Dox mice; however, the
air spaces were not as large in the CCSPrtTA//(tetO)7TGF-
/ as in the SP-C-TGF- mice. Although type II cell
numbers for total lung and per body weight were not affected
in SP-C-TGF- mice, a threefold increase in type II cell
numbers (per total lung and per body weight) was observed
after 6 wk of Dox treatment in the CCSPrtTA//(tetO)7TGF-
/ mice. Eighteen percent of type II cells were embedded in
the ﬁbrotic region in SP-C-TGF- mice (Table 2), and embed-
ded type II cells in the CCSPrtTA//(tetO)7TGF-/ mice
were 10%. Therefore, the number of nonembedded type II cells
in the total lung was decreased 30% in the SP-C-TGF- mice
and increased threefold in the CCSPrtTA//(tetO)7TGF-/
mice compared with the number of type II cells in the control
mice group. There were no ﬁbrotic regions in the nontrans-
Fig. 6. Localization of type II cells in CCSPrtTA//(tetO)7TGF-/ mice.
Type II cells were identiﬁed by immunostaining with pro-SP-C antibody
(arrows). A: control mice were CCSPrtTA/ mice treated with doxycycline;
type II cells were in the normal position in the alveoli. B: in CCSPrtTA//
(tetO)7TGF-/ mice treated with doxycycline for 6 wk, type II cells were
detected within ﬁbrotic lesions. Images are representative of lung sections from
4 distinct mice. Scale bars are 50 m.
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SP-C-TGF- mice than in CCSPrtTA//(tetO)7TGF-/
mice, resulting in a higher % of type II cells that were found
embedded in matrix in SP-C-TGF- mice.
Surfactant Proteins and Surfactant Function
The content of SP-A, -B, -C, and -D in BALF containing the
same amount of Sat PC was analyzed by Western blot (Fig.
7A). From the total volume of BALF and the aliquot volume
used for Western blot, surfactant protein content in total BALF
was determined (Fig. 7B). Expression of TGF- decreased
content of all the surfactant proteins in BALF, whereas surfac-
tant protein mRNAs were unchanged (Fig. 7C). Equilibrium
surface tension of large aggregate surfactants adjusted to the
same concentration of phospholipid were similarly low for
both groups, but initial time to reach equilibrium surface
tension was signiﬁcantly slower (P 	 0.05) for surfactant from
SP-C-TGF- mice (Fig. 8A). Large aggregate surfactant iso-
lated from SP-C-TGF- mice had a signiﬁcantly higher mini-
mum surface tension (Fig. 8B).
The content of SP-A and SP-B in BALF was decreased and
SP-C and SP-D were unchanged in CCSPrtTA//(tetO)7TGF-
/ mice (Fig. 9A). Surfactant protein mRNAs (Fig. 9B) were
unchanged in CCSPrtTA//(tetO)7TGF-/ mice. Surface ac-
tivity of isolated large aggregate surfactant from CCSPrtTA//
(tetO)7TGF-/ mice was altered, with mean minimum sur-
face tension of 13 mN/m (Fig. 8, C and D). Altered surfactant
protein content, especially decreased SP-B in SP-C-TGF-
mice and CCSPrtTA//(tetO)7TGF-/ mice BALF, may
have inﬂuenced surfactant function.
Expression of a Dominant Negative EGFR Corrects
Surfactant Metabolism and Lung Morphology
As previously reported, enlarged air spaces and ﬁbrosis seen
in SP-C-TGF- mice were substantially corrected, and type II
cells shown by pro-SP-C immunostaining were distributed
normally in SP-C-TGF-/EGFR-M mice (Fig. 10D) (16). Sat
PC level and % secretion in SP-C-TGF-/EGFR-M mice were
similar to nontransgenic mice (Fig. 10, A and B). Incorporation
of [3H]palmitic acid into Sat PC and % [3H]Sat PC secreted in
BALF at 8 h after precursor injection was similar to that of
nontransgenic mice (Fig. 10C). Surfactant pool sizes and me-
tabolism were similar to controls in the SP-C-TGF-/EGFR-M
mice lung. Thus expression of the dominant negative EGFR in
respiratory epithelial cells blocked effects of TGF- on lung
morphology and surfactant homeostasis.
Fig. 7. Decreased surfactant proteins in SP-C-TGF- mice. A: SP-A, SP-B,
SP-C, and SP-D were quantitated in BALF by Western blot analyses (repre-
sentative Western blot shown at top). Samples were loaded with the same
amount of Sat PC. B: surfactant protein content in total BALF was quantitated
by densitometry and determined from the total volume of BALF and the
aliquot volume loaded for Western blot. Controls were assigned a value of 1
(n  6/group). All the surfactant proteins were signiﬁcantly decreased in
SP-C-TGF- mice compared with nontransgenic mice. C: SP-A, SP-B, and
SP-C mRNA were quantitated using an S1 nuclease assay. Results were
standardized to L32 mRNA and normalized to nontransgenic mice. SP-A
mRNA, SP-B mRNA, and SP-C mRNA in SP-C-TGF- mice were similar to
that in nontransgenic mice. N  4/group, *P 	 0.05 vs. nontransgenic mice.
Table 1. Morphological analysis
n Body Weight, g
Lung
Volume, ml
Lung Volume,
ml/kg body weight n % Parenchyma
Type II
Cells/Lung, 106
Type II Cells/g
body weight, 105
Nontransgenic 7 26.80.7 0.830.04 3113 1 9 1 9.73.5 3.51.1
SP-C-TGF- 7 20.10.6* 0.780.03 382* 3 162* 8.00.5 4.10.5
Control 7 30.91.7 0.920.06 3013 1 7 2 9.22.7 3.10.8
CCSPrtTA//(tet07)TGF-/ 7 31.41.7 1.330.03* 433* 3 181 32.13.0* 10.31.2*
n, Number of mice. *P 	 0.01 vs. nontransgenic or control group. TGF, transforming growth factor; SP, surfactant protein.
Table 2. Degree of ﬁbrosis and type II cell embedment
n %Fibrotic Region %Embedded Type II Cells
SP-C-TGF- 3 42.93.0* 18.03.1*
CCSPrtTA//(tet07)TGF-/ 3 32.81.6 9.91.1
*P 	 0.05 vs. CCSPrtTA//(tetO7)TGF-/.
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Percent secretion of surfactant phospholipid from type II
cells was not affected by 3-h exposure to a wide range of 5–250
ng of TGF-/well (Table 3). Secreted SP-B from type II cells
was similar (by ANOVA) after 3-h exposure to 0–250 ng of
TGF-/well. There was no direct inﬂuence of TGF- on
surfactant phospholipid and SP-B secretion by type II cells in
culture.
DISCUSSION
Increased expression of TGF- in epithelial cells of the lung
decreased surfactant secretion and increased surfactant content
in the tissue. Enlarged hypoplastic alveoli and ﬁbrotic lesions
seen in the TGF--expressing mice were similar to ﬁndings in
infants and animal models with BPD (8, 19). TGF- caused
tissue remodeling with resultant embedment of type II cells
within the ﬁbrotic lesions. Abnormalities in surfactant secre-
tion in TGF- mice are probably related, at least in part, to
tissue remodeling that limits surfactant secretion.
The presence of EGFR in rat type II cells in culture and its
binding speciﬁcity were previously shown (38). Isolated type II
cells from adult rabbit lung and H441 cells, a pulmonary
epithelial cell line, in culture proliferate in response to TGF-
via EGFR (5). Furthermore, we have conﬁrmed the presence of
EGFR in mouse type II cells in culture (on days 5 and 7)b y
immunostaining using EGFR primary antibody (Upstate Bio-
technology, Lake Placid, NY) and second antibody, Alexa
Fluor 568 (Molecular Probes, Eugene, OR). Immunohisto-
chemical staining of EGFR on cultured mice type II cells was
strong, whereas control with only a second antibody did not
show any staining (data not shown). TGF- did not affect
surfactant secretion when added directly to the media of
cultured type II cells. We used 5–250 ng of TGF-/well, and
100 ng/well was the highest amount of TGF- used by others
for the studies with cultured cells (17, 24, 40). With the use of
a similar method of cultured type II cells, a twofold increase in
surfactant secretion was previously shown to be induced by
phorbol 12-myristate 13-acetate (39), demonstrating the utility
of the cultures. The lack of a direct effect of TGF- on
surfactant secretion by type II cells suggests that altered sur-
factant secretion may be a consequence of TGF--induced
alterations in lung structure in vivo. Despite high tissue levels
of TGF- in SP-C-TGF-/EGFR-M mice, surfactant pool size
and secretion were normalized by expression of a dominant
negative EGFR in respiratory epithelial cells. The inhibition of
TGF--induced signaling through the EGFR in distal epithelial
cells corrected TGF--induced ﬁbrosis (16) and surfactant
secretion.
In the present study, the decrease in SP-B in BALF from
SP-C-TGF- mice ranged between 36 and 51% of normal
mouse level, a level similar to that in SP-B(/) mouse lung.
Heterozygous SP-B(/) mice with 50% of normal SP-B
Fig. 8. Surface tension of isolated surfactant. A: equilibrium surface tension of large aggregate surfactant isolated from BALF from SP-C-TGF- mice and
nontransgenic mice. Large aggregate surfactant containing 7 nmol of phospholipid was applied to the air-liquid interface of the captive bubble surfactometer.
Change in the shape of static bubble from rounded to discoid was monitored for 300 s and used to calculate equilibrium surface tension. The time to reach the
equilibrium surface tension was somewhat slower for surfactant from SP-C-TGF- mice, and surface tension was higher at 1 s. Equilibrium surface tension was
very similar after 60 s of measurements between 2 groups. N  3 pool, 2 mice/pool; *P 	 0.05 vs. nontransgenic mice. Standard error bars (not shown) were
within the symbol mark. B: minimum surface tension was achieved by cycling the bubble to 20% reduction of the original bubble size at rate of 12 cycles/min
and recorded on the 5th cycle. Minimum surface tension was signiﬁcantly higher for surfactant from SP-C-TGF- mice, whereas surfactant from nontransgenic
mice showed normal, low minimum surface tension. Equilibrium surface tension (C) and minimum surface tension (D) of large aggregates from CCSPrtTA//
(tetO)7TGF-/ mice were studied. The minimum surface tension was higher for surfactant from CCSPrtTA//(tetO)7TGF-/ mice. N  3 pool, 2
mice/pool; *P 	 0.05 vs. control mice surfactant.
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housed in conditions of no stress. However, SP-B(/) mice
are more susceptible to stress caused by hyperoxia (50). Lung
inﬂammation induced by intratracheal injection of endotoxin
was less severe in mice with higher SP-B levels than SP-
B(/) mice (11). SP-B is the singularly required critical
component to form a stable high surface-active pulmonary
surfactant ﬁlm (6, 35). The conditional SP-B(/) mice had
severe respiratory distress and died when SP-B was decreased
to 25% of normal levels (34). In the present study, decreased
SP-B was associated with higher minimum surface tension of
isolated surfactant from SP-C-TGF- mice. Decreased levels
of mature SP-B in SP-C-TGF- mice were not due to an SP-B
processing problem because pro-SP-B was not detected in
BALF by Western blot (data not shown). The mechanisms by
which TGF- decreased SP-B is presently unknown. Because
SP-B mRNA levels were normal, TGF- might also perturb
SP-B secretion and access to the alveoli. In SP-C-TGF- mice,
SP-A and SP-D levels in BALF were also decreased more than
that for nontransgenic mice. SP-A and SP-D play roles in host
defense of the lung, including clearance and killing of both
bacteria and viruses and regulation of the inﬂammatory re-
sponses in the lung (33). Lower levels of SP-A and SP-D seen
in the alveoli of the TGF--expressing mice might render the
mice susceptible to lung inﬂammation. A higher incidence of
lung infection and prolonged lung inﬂammation in patients
with pulmonary ﬁbrosis and emphysema might, at least par-
tially, be related to changes in concentrations of surfactant
proteins associated with lung remodeling.
Whereas effects of TGF- on surfactant phospholipid secre-
tion were similar in SP-C-TGF- mice and CCSPrtTA//
(tetO)7TGF-/ mice, lung morphology was distinct for each
model. In SP-C-TGF- mice, lung volume was not signiﬁ-
cantly increased but percent parenchyma was signiﬁcantly
decreased. The larger alveolar air space was the result of a lack
Fig. 9. Decreased SP-A and SP-B content in BALF from CCSPrtTA//
(tetO)7TGF-/ mice. A: SP-A and SP-B contents in total BALF quantitated
by Western blot analyses were decreased in CCSPrtTA//(tetO)7TGF-/
mice (n  4/group). B: SP mRNAs in CCSPrtTA//(tetO)7TGF-/ mice
were similar to that in control mice. Induction of TGF- in adults did not affect
SP mRNA levels. *P 	 0.05 vs. control.
Fig. 10. Sat PC content and secretion are not altered in bitransgenic SP-C-
TGF-/SP-C-EGF receptor (EGFR)-M mice. A and B: Sat PC level and %
secretion or % Sat PC in BALF relative to total lung in SP-C-TGF-/SP-C-
EGFR-M mice were similar to those in nontransgenic mice. C:%[ 3H]Sat PC
in BALF relative to total lung at 8 h after [3H]palmitic acid injection was
unchanged, and surfactant pool sizes and secretion were similar to controls in
the SP-C-TGF-/SP-C-EGFR-M mice. D: normal type II cell distribution
(detected by immunostaining with anti-pro-SP-C antibody, arrows) in the
SP-C-TGF--EGFR-M mice. Image is representative of lung sections from 4
distinct mice. Scale bar is 50 m.
Table 3. TGF- does not inﬂuence secretion of surfactant by
cultured type II cells
n
TGF-, ng/well
0 5 50 250
%Secretion of
[3H]phosphatidylcholine 3 11.90.5 10.60.3 12.70.4 12.40.5
Secreted SP-B into media 3 10 0.980.15 1.070.07 1.100.16
Values are expressed relative to 0 ng TGF- control group (value  1); n 
number of experiments/group.
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contrast, in the CCSPrtTA//(tetO)7TGF-/ mice, the lung
volume was increased 1.5-fold. The functional area of paren-
chyma in CCSPrtTA//(tetO)7TGF-/ mice was the same
as control and resulted in increased alveolar air space. Num-
bers of type II cells were measured threefold in CCSPrtTA//
(tetO)7TGF-/ mice. In contrast, type II cell numbers in
SP-C-TGF- mice were similar to nontransgenic mice. A
higher percentage of parenchyma was ﬁbrotic, and more type II
cells were embedded in ﬁbrotic lesions in SP-C-TGF- mice
compared with CCSPrtTA//(tetO)7TGF-/ mice. The
degree of decrease in surfactant protein contents in BALF
was also higher in SP-C-TGF- mice than CCSPrtTA//
(tetO)7TGF-/ mice. These differences in surfactant protein
contents are associated with higher surface tension of isolated
surfactant from SP-C-TGF- mice compared with that from
CCSPrtTA//(tetO)7TGF-/ mice. These differences in
the two models are likely related to the time and/or duration of
TGF- expression. Lung remodeling, decreased surfactant pro-
teins in BALF, and altered surface activity of surfactant were
more severe when TGF- was expressed throughout lung
development compared with 6 wk in adults.
In patients with lung injury, extensive damage to the alve-
olar epithelium and vascular endothelial cells can cause in-
creased protein permeability with resultant extravasation of
protein-rich edema ﬂuid into the air spaces that can inhibit
surfactant activity and alter pulmonary function. Increased
inﬂammatory cells synthesize and secrete various cytokines,
including IL-6 and IL-1, which are associated with increased
EGF and TGF-. IL-1 induced alveolar epithelial wound
repair by EGF- or TGF--dependent mechanisms in vitro (13,
24), demonstrating a role of TGF- in repair of lung injury.
The various cytokines and growth factors, including TGF-,
activate STAT-3, which mediates a wide variety of cellular and
organ responses to inﬂammation (1). Activated STAT-3 is also
known to increase expression of TGF- in many organs and
malignant cells (12, 43), whereas the signaling mechanisms for
induction of TGF- in injured lung are unknown.
The present study demonstrates that expression of TGF- in
the developing and adult lung altered surfactant phospholipid
and SP-B secretion in vivo. Abnormalities in surfactant ho-
meostasis in clinical conditions, such as BPD and lung recov-
ery from acute respiratory distress syndrome, may be related in
part to TGF--induced tissue remodeling that limits surfactant
secretion. Although multiple factors are likely to play roles in
the pathogenesis of BPD and other forms of chronic lung
injury, the present study supports the concept that TGF- may
play a role in altered surfactant protein homeostasis and sur-
factant function that are often associated with lung injury and
remodeling.
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